The startup operates a therapeutic discovery platform that provides scientific support and funding to early-stage life science assets, facilitating their transformation into investable opportunities. By de-risking the development of breakthrough life science innovations, the platform enables companies to advance their programs with greater financial and operational confidence.
Funding
$11.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early-stage life science assets often lack the necessary funding and scientific support to progress from initial discovery to viable investment opportunities. This gap hinders the development of potentially breakthrough therapeutic innovations.
Solution
Epidarex Exeed operates a therapeutic discovery platform that provides early-stage life science assets with both funding and hands-on scientific support. The platform applies drug discovery and project management expertise to de-risk and transform these innovations into investable opportunities. By providing resources and guidance, Epidarex Exeed enables the progression of promising therapeutic concepts, increasing their attractiveness for company creation and Series A investment. This approach facilitates the translation of breakthrough science into tangible assets ready for further development.
Target Audience
The primary target audience includes researchers, scientists, and early-stage life science companies with innovative therapeutic concepts requiring funding and development support.
Features
- Hands-on scientific support for early-stage life science assets
- Funding to drive drug discovery projects
- Application of drug discovery and project management capabilities
- De-risking of therapeutic opportunities
- Transformation of innovations into investable assets
- Focus on breakthrough science